Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

This study is testing a combination of two immune-boosting drugs — low-dose interleukin-2 (IL-2) and pembrolizumab — as a first-line treatment for stage IV (advanced) non-small cell lung cancer (NSCLC). IL-2 helps activate immune cells, while pembrolizumab removes the brakes that cancer cells use to hide from the immune system. Researchers hope the combination is more effective than either drug alone. **You may be eligible if...** - You are 18 or older with stage IV non-small cell lung cancer (adenocarcinoma or squamous cell type) - You have had no prior treatment for advanced NSCLC - Your cancer has at least one measurable spot on scans - You are in reasonably good health (ECOG 0–2) - You have a life expectancy of at least 12 weeks - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have active, untreated autoimmune disease - You are on long-term steroid medications - You have had a prior organ or stem cell transplant - You are pregnant or breastfeeding - You have uncontrolled infections or serious heart or lung conditions Talk to your doctor to see if this trial is right for you.